Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Comparing Sequential Satraplatin and Erlotinib to Single-Agent Erlotinib in Patients ≥ 70 Years of Age With Unresectable Stage 3 OR 4 Non-Small Cell Lung Cancer as 1st-Line Therapy

NCT00370383 is registered in ClinicalTrials.gov with Agennix as lead sponsor.

NCT NCT00370383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00370383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Comparing Sequential Satraplatin and Erlotinib to Single-Agent Erlotinib in Patients ≥ 70 Years of Age With Unresectable Stage 3 OR 4 Non-Small Cell Lung Cancer as 1st-Line Therapy
Lead sponsor
Agennix
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2006
Completion date
March 31, 2009
Enrollment
100 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer